
Topic
Transurethral Resection of Bladder Tumor (TURBT)
Podcasts
Urology # 340Nov 3, 2026Understanding Intermediate-Risk Bladder Cancer

By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, treat in the office, or start intravesical therapy. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Wesley Yip, urologic oncologist at City of Hope, to rethink what she calls the forgotten stepchild of bladder cancer: intermediate-risk non-muscle invasive bladder cancer (NMIBC). Dr. Yip explains why he sees the category as a catch-all rather than a single biological entity, by his estimate covering 50 to 60 percent of NMIBC, why he now relies on the International Bladder Cancer Group (IBCG) definition, and why tumor grade comes first, ahead of multiplicity, size, and recurrence timing.
Urology # 323Aug 11, 2026Managing Intermediate-Risk Bladder Cancer

Recurrent low-grade, intermediate-risk bladder cancer presents a unique treatment challenge: recurrence is common, progression is uncommon, and the burden of repeated procedures can add up quickly. On this episode of the BackTable Urology Podcast, Dr. Ruchika Talwar interviews Dr. Charles "Chas" Peyton about how to manage intermediate-risk bladder cancer patients while balancing disease control and quality of life. They discuss the cumulative impact of repeated TURBTs and explore the evolving role of office-based treatments and chemoablative therapies as alternatives to the traditional treatment cycle.
Tumor Board # 67Jun 18, 2026Bladder Cancer Risk Stratification: Best Practices

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes.
Urology # 310Jun 18, 2026Bladder Cancer Risk Stratification: Best Practices

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes.
Urology # 308Jun 11, 2026Navigating Shared Decision-Making in Bladder Cancer Treatment

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue DNP join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy.
Tumor Board # 65Jun 11, 2026Navigating Shared Decision-Making in Bladder Cancer Treatment

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue DNP join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy.
Urology # 275Nov 21, 2025NMIBC Tumor Board: Nuances in Management

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios.
Urology # 266Oct 17, 2025Guide to Patient-Centered Counseling in NMIBC Care

When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer.
Tumor Board # 30Oct 7, 2025NMIBC Tumor Board: Nuances in Management

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios.
Tumor Board # 25Oct 7, 2025Guide to Patient-Centered Counseling in NMIBC Care

When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer.
Urology # 245Jul 1, 2025Intravesical Therapies for Intermediate Risk Bladder Cancer

With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.
Urology # 243Jun 24, 2025Intermediate Risk NMIBC: Patient-Centered Treatment Strategies

Counseling patients with intermediate-risk non-muscle invasive bladder cancer can be complex, with a wide range of treatment options and care pathways. In this episode of BackTable Urology, urologic oncologists Dr. Ruchika Talwar and Dr. Kelly Bree explore how to approach this challenge with clarity and compassion.
Tumor Board # 19Jun 17, 2025Intravesical Therapies for Intermediate Risk Bladder Cancer

With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.
Tumor Board # 18Jun 10, 2025Intermediate Risk NMIBC: Patient-Centered Treatment Strategies

Counseling patients with intermediate-risk non-muscle invasive bladder cancer can be complex, with a wide range of treatment options and care pathways. In this episode of BackTable, urologic oncologists Dr. Ruchika Talwar and Dr. Kelly Bree explore how to approach this challenge with clarity and compassion.
Urology # 204Dec 6, 2024Managing Low & Intermediate Risk Bladder Cancer

Stay up to date in your bladder cancer practice with this insightful episode of the BackTable Urology podcast, developed in collaboration with the Society of Urologic Oncology. Dr. Betsy Koehne (University of Wisconsin) and Dr. Amir Salmasi (UC San Diego) talk through the contemporary management of low and intermediate-risk non-muscle-invasive bladder cancer.
Urology # 186Aug 27, 2024Blue Light Cystoscopy: Improving Bladder Cancer Detection

What is the role of blue light cystoscopy in bladder cancer? In this episode, Dr. Suzette Sutherland interviews Dr. Suzanne Merrill from Colorado Urology about the benefits of this technology in the diagnosis and treatment of bladder cancer, and how to implement it into your practice.
Urology # 177Jul 9, 2024Latest Approaches to Treat High-Risk NMIBC

Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.
Urology # 157Mar 19, 2024The Bladder Cancer Matters Podcast

In this special crossover episode with the Bladder Cancer Matters podcasts, Rick Bangs, a bladder cancer survivor, and Dr. Aditya Bagrodia, a urologic oncologist, discuss shared decision-making in bladder cancer treatment.
Industry # 64Nov 14, 2023Redefining Surgery: Virtuoso’s Robotic Precision

In this episode, host Dr. Jose Silva speaks with Dr. Duke Herrell, CEO and CMO of Virtuoso Surgical, a robotic surgery tool known for its exceptional dexterity and precision.
Urology # 137Nov 14, 2023Redefining Surgery: Virtuoso’s Robotic Precision

In this episode, host Dr. Jose Silva speaks with Dr. Duke Herrell, CEO and CMO of Virtuoso Surgical, a robotic surgery tool known for its exceptional dexterity and precision.
Urology # 57Sep 28, 2022Blue Light Cystoscopy: Who, When, and How?

In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with urologist Dr. Anne Schuckman from the University of Southern California about advantages and advice for blue light cystoscopy, a procedure performed to identify bladder tumors during transurethral resection of bladder tumor (TURBT).
Urology # 46Jul 20, 2022Techniques & Maneuvers for Optimal TURBT

In this episode of BackTable Urology, Dr. Aditya Bagrodia interviews Dr. Sam Chang, chief of urologic oncology at Vanderbilt University, about surgical tips and tricks for intermediate and high risk bladder cancer.
Urology # 25Dec 15, 2021Management of Muscle Invasive Bladder Cancer

We talk with Dr. Siamak Daneshmand, Director of Urologic Oncology at USC Institute Of Urology, about the management of muscle-invasive bladder cancer. Listen to the full episode to learn tips for successful transurethral resections of bladder tumor (TURBT) and cystectomies, using imaging to stage bladder cancers, deciding between a cystectomy vs. trimodality therapy (TMT), and comparisons between neobladder procedures and urinary diversions.
Urology # 2Apr 16, 2021Management of Bladder Cancer

Dr. Jose Silva talks with Urologist Dr. Aditya Bagrodia from UT Southwestern Medical Center about the medical and surgical management of bladder cancer.